TVS Motor is infiltrating more in Ultraviolette EV

Image
Ultraviolette EV has announced that they have received Rs.30 Cr as apart of Series B investment from TVS motors today. The picture was taken during the F77 Launch event The EV is the future of transportation as almost all the automobile companies are trying to enter or establish their own EV product line. Companies like TESLA, Rivian, AUDI, BMW and a few others had already made their impression in EV. But in India, the story is different because there are very few EV players on a small scale level. Companies like TATA and Hero moto corp are investing nickles and dimes many EV startups like Tork motors and Ather Energy. An Inside outlook to F77 Likewise, TVS motors have invested in Ultraviolette Automotive an EV startup based on Karnataka, India. They made an initial investment of Rs.11 Cr around 2017, Then extended their investment by preference share of Rs.5 Cr in last fiscal. But in today’s news Ultraviolette Automotive has said that they have risen another Rs.30 Cr as a part of the...

Finally Glenmark! This might be the cure we all are waiting for 10months.


FabiFlu will be the first Favipiravir-approved by DCGI for the treatment of Covid-19, the company said in a statement.

Finally Glenmark! This might be the cure we all are waiting for 10months.

On Friday 19th June 2020, Glenmark a Mumbai based Pharma company received approval from Drugs Controller General of India(DCGI), for manufacturing of antiviral drug for the treatment of patients with mild to moderate COVID-19. The brand today has launched the product Favipiravir under its brand name FabiFlu. “This approval comes at a time when cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” said Glenn Saldanha, Glenmark Pharmaceuticals Chairman and MD.


“Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country,” Saldanha said. The drug will be available only as a prescription-based medication for Rs.103/tablet, with recommended dose being 1,800 mg 2/day one, followed by 800mg 2/daily up to day14. (Bloomberg)


Comments

Post a Comment

Most Read

Sony will focus and increase it’s overall value, as the company has decided to change the name after 62 years:

TVS Motor is infiltrating more in Ultraviolette EV